论文部分内容阅读
目的:探讨应用泼尼松龙、复方异丙托溴胺与抗生素类药物联合治疗的方法对急性加重期慢性阻塞性肺疾病患者的临床效果和安全性。方法:将2010年10月至2012年12月收治的急性加重期慢性阻塞性肺疾病患者86例随机分为对照组和治疗组各43例,对照组按急性加重期慢性阻塞性肺疾病常规治疗,治疗组在对照组治疗的基础上加用泼尼松龙、复方异丙托溴胺治疗,比较两组临床疗效和不良反应。结果:治疗组临床效果明显优于对照组(P<0.05);治疗后治疗组肺功能的改善幅度明显优于对照组(P<0.05);且治疗组未出现明显的不良反应。结论:应用泼尼松龙、复方异丙托溴胺与抗生素类药物联合治疗急性加重期慢性阻塞性肺疾病患者的临床效果好,且无明显不良反应。
Objective: To investigate the clinical efficacy and safety of the combination therapy of prednisolone, ipratropium bromide and antibiotics in patients with acute exacerbation of chronic obstructive pulmonary disease. Methods: From October 2010 to December 2012, 86 patients with acute exacerbation of chronic obstructive pulmonary disease were randomly divided into control group and treatment group, 43 cases in each group. The control group was treated by conventional treatment of chronic obstructive pulmonary disease , The treatment group in the control group based on the treatment plus prednisolone, compound ipratropium bromide treatment, the two groups were compared the clinical efficacy and adverse reactions. Results: The clinical effect of the treatment group was significantly better than that of the control group (P <0.05). After treatment, the improvement of lung function in the treatment group was significantly better than that in the control group (P <0.05). No obvious adverse reactions were found in the treatment group. Conclusion: The combination of prednisolone, ipratropium bromide and antibiotics in patients with acute exacerbation of chronic obstructive pulmonary disease clinical effect is good, and no significant adverse reactions.